Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00360035 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia
A Phase 2 study of Myelofibrosis, sponsored by Gemin X.
- Completed
- Registry status
- Phase 2
- Development phase
- 22
- Enrollment target
- 7
- Study locations
NCT00360035 is a Phase 2 study of Myelofibrosis that has completed, run by Gemin X. The registered enrollment target is 22 participants, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (89% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT00360035, a Phase 2 study of Myelofibrosis, has completed, sponsored by Gemin X.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 22 participants
- Enrollment target
- 7
- Study locations
Study Summary
Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often inhibited in cancer cells.
Conditions Studied
Interventions
- DRUG Obatoclax mesylate (GX15-070MS)
Study Locations (7)
District of Columbia
- Georgetown University Medical Center - Washington D.C.
Florida
- James A. Haley Veterans Hospital - Tampa
Georgia
- Emory University - Atlanta
Illinois
- The University of Chicago - Chicago
Massachusetts
- University of Massachusetts Medical Center - Worcester
Texas
- MD Anderson Cancer Center - Houston
Ontario
- Princess Margaret Hospital - Toronto
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22 participants |
| Start Date | 2006-07 |
| Est. Completion | 2009-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00360035
The ClinicalTrials.gov registry entry for NCT00360035 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 22 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 196-participant average among 61 other Myelofibrosis trials with a reported enrollment target (89% lower). The listed sponsor is Gemin X, which has 11 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Myelofibrosis appearing as the primary indexed condition, and to 1 intervention - of which Obatoclax mesylate (GX15-070MS) is the first listed.
NCT00360035 reports 7 study locations spanning 7 distinct geographic areas - top geographies include District of Columbia, Florida, Georgia.
Frequently Asked Questions
What is clinical trial NCT00360035 about?
NCT00360035 is a clinical study titled "Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in the Treatment of Myelofibrosis With Myeloid Metaplasia". Defects in the apoptotic process can lead to the onset of cancer by allowing cells to grow unchecked when an oncogenic signal is present. Obatoclax is designed to restore apoptosis through inhibition of the Bcl-2 family of proteins, thereby reinstating the natural process of cell death that is often...
What is the current status of trial NCT00360035?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 22 participants. The study started on 2006-07. Estimated completion is 2009-02.
What conditions does trial NCT00360035 study?
This clinical trial studies the following conditions: Myelofibrosis.
What interventions are being tested in trial NCT00360035?
The interventions under investigation include: Obatoclax mesylate (GX15-070MS) (DRUG).
Who is sponsoring clinical trial NCT00360035?
This trial is sponsored by Gemin X, which has 11 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00360035 being conducted?
This trial has 7 study locations across District of Columbia, Florida, Georgia, Illinois, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myelofibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of TL-895 in Subjects With Myelofibrosis or Indolent Systemic Mastocytosis
RECRUITING · Phase 2
-
Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders
RECRUITING · Phase 2
-
A Study of Selinexor Monotherapy in Subjects With JAK Inhibitor-naïve Myelofibrosis and Moderate Thrombocytopenia
RECRUITING · Phase 2
-
High Dose Ruxolitinib and Allogeneic Stem Cell Transplantation in Myelofibrosis Patients With Splenomegaly
RECRUITING · Phase 2
-
CMV-MVA Triplex Vaccination in HLA-Matched Related Stem Cell Donors for the Prevention of CMV Infection in Patients Undergoing Hematopoietic Stem Cell Transplant
RECRUITING · Phase 2
-
Curcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.